With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-95-9,4-Bromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.
In a flame dried 50-mL 3-neck flask fitted with a condenser, a mixture of anthraceneboronic acid 35-7 (522 mg, 0.985 mmol), 4-bromo-2,2?-bipyridine (154 mg, 0.657 mmol), and cesium carbonate (640 mg, 1.97 mmol) in EtOH (15 mL) and water (2 mL) was degassed by refluxing under argon stream for 75 minutes. Then Pd(OAc)2 (29.7 mg, 0.131 mmol) and PPh3 (138 mg, 0.526 mmol) were added in one portion. Refluxing under argon was continued until the reaction was complete in 90 minutes. The reaction mixture was then allowed to cool to room temperature and filtered; the solid residue was rinsed with DCM and MeOH. The filtrate was concentrated in vacuo, and the resulting residue was purified by reversed-phase flash chromatography (C18 190 SiO2, eluted with gradient of 0.09% 58 HCl in 23 MeOH). The pure product was isolated by basification of combined and concentrated fractions with solid 43 NaHCO3 (200 mg) followed by extraction with DCM twice. The combined DCM layers were then dried over MgSO4 and concentrated in vacuo to yield 192 product as a yellow solid (316 mg, 50%).
14162-95-9, 14162-95-9 4-Bromo-2,2′-bipyridine 12087122, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; Profusa, Inc.; GAMSEY, Soya; BERNAT, Viachaslau; KUTYAVIN, Alex; CLARY, Jacob William; PRADHAN, Sulolit; (192 pag.)US2018/179233; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI